| 王雪鹃,王荣福,杨志,林保和,徐冰,张岩,张梅颖.前哨淋巴结示踪剂99Tcm-IT-Rituximab的制备及初步动物实验研究[J].中国医学影像技术,2006,22(1):139~143 |
| 前哨淋巴结示踪剂99Tcm-IT-Rituximab的制备及初步动物实验研究 |
| Sentinel lymph node imaging with a novel radiotracer:preparation of 99 Tcm-IT2Rituximab and experimental study |
| 投稿时间：2005-09-19 修订日期：2005-11-02 |
| DOI： |
| 中文关键词: 前哨淋巴结 示踪剂 99Tcm-IT-Rituximab 淋巴显像 |
| 英文关键词:Sentinel lymph node Radiot racer 99 Tcm-IT-Rituximab Lymphoscintigraphy |
| 基金项目: |
|
| 摘要点击次数: 2437 |
| 全文下载次数: 63 |
| 中文摘要: |
| 目的 研究新型特异性前哨淋巴结(SLN) 示踪剂99 Tcm-IT-Rituximab 的定位效应。方法 采用22亚氨基噻吩(22IT) 修饰法制备99 Tcm-IT-Rituximab ,并评价其定位SLN 的生物性能,监测注射显像剂的化学剂量及注射体积对SLN 摄取的影响。结果 99 Tcm-IT-Rituximab 标记率大于90 % ,分子保持完整。99 Tcm-IT-Rituximab 可清晰定位小鼠SLN ,注射后30 min 到24 h SLN 均可显影,未见次级淋巴结显影。注药后24 h SLN ID %值为4.49 % ,次级及第三级淋巴结ID %摄取率比值相当于本底,24 h 注射点滞留率为22. 14 %。示踪剂的化学量及注射体积均影响SLN 显像。随着二者的增加,SLN %ID 值逐渐减少,次级及第三级淋巴结%ID 值均逐渐上升。结论 99 Tcm-IT-Rituximab 的标记方法简单,研究结果表明其具有潜在的临床应用价值。 |
| 英文摘要: |
| Objective To investigate the located ability of a novel sentinel lymphoscintigraphy agent , 99Tcm-IT-Rituximab ,in detecting the sentinel lymph node (SLN). Methods 99 Tcm-Rituximab was prepared indirectly via 22iminothiolane (22IT)conjugation and labeled with techenium299m. The locating ability of 99 Tcm-IT-ituximab was evaluated with biological dist ri2 bution result s in mice , and the influenced factors on the imaging by the injecting dosage and volume were also observed in mice. Results 99 Tcm-IT-Rituximab , with a yield of about 90 % , were intact . The result s of the dynamic SLN mapping showed that SLN could be seen within a wide range f rom 30 min to 24 h af ter injecting , and higher order nodes had not been visualized all the time. The result s of the biodist ribution showed that SLNs could be identified by the imaging agent,99 Tcm-IT-Rituximab , successfully , the rate of uptake in 24 h was about 4. 49 % , while the uptake of higher echelon lymph node was close to background. SLN imaging would be influenced by the dosage and volume of radiot racer , which could both result in the decrease of SLN uptake and the increase of higher order nodes uptake. Conclusion The labeling method is simple and safe. 99 Tcm-IT-Rituximab appears to be potential and useful for clinical SLN study. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
